Pomeroy Moving On, Will Leave Stem Cell Board
By Dr. Matthew Watson
Claire Pomeroy, one of the longtime
members of the governing board of the $3 billion California stem cell agency,
will be leaving her position at UC Davis and the stem cell board next
June.
dean of the medical school. In a telephone interview, she told the
California Stem Cell Report that she is examining a “few select
opportunities” to work at a national level on health reform and
health policy issues.
 |
| Claire Pomeroy UC Davis photo |
Washington, D.C., working on health issues on behalf of the
University of California during the transition period before she
leaves her position in California.
shortly before the Golden State's stem cell agency was created in
2004. At that time, UC Davis had what she called a “fledgling”
stem cell research effort. Today the school has chalked up $128 million in
grants from the stem cell agency, ranking fifth among institutions
funded by the agency.
agency “catalyzed development of our program,” which she said has
risen to “national prominence.”
agency board was also instrumental in attracting a $100 million grant
from the Moore Foundation to start a new school of nursing at UC
Davis in 2009. Through her service on the board, she met Ed Penhoet,
who also served on the board and was one of the co-founders of Chiron
and then president of the Moore Foundation. Subsequently, Penhoet
called her for lunch to discuss her thoughts on nursing education,
and developments moved on from there.
nation's largest grant for nursing education, according to the Moore Foundation.
Source:
Stem Cell Therapy
Comments Off on Pomeroy Moving On, Will Leave Stem Cell Board |
November 25th, 2012
‘The Knoepfler Award:’ Recognizing Risk and Those Who Make a Difference
By Dr. Matthew Watson
A UC Davis stem cell researcher-blogger has announced a “stem cell person of the year” award
complete with a $1,000 cash prize that he is putting up himself.
stem cell scientist in the U.S. actively blogging on the subject,
said he has decided to put his money where his mouth is.
including one for a scientist. Three days after the item aappeared, UC Davis
featured Knoepfler in a press release that included a video of
Knoepfler explaining the effort.
 |
| Paul Knoepfler UC Davis photo |
He said he wanted to go beyond “old
fashioned awards” given by “stodgy committees.” Knoepfler said he
is seeking to recognize that stem cell research is “transcending the
lab.”
is “to advance the stem cell field and give credit to those who
make a real difference.”
“The criteria are that the person
made a truly outstanding difference in the stem cell field for 2012.
The winner could be a scientist, a patient advocate, someone in
industry, a student, a physician…really anyone who has made the
field better. For non-scientist nominees I’m particularly
interested in those who took personal risks or gave of themselves to
help others. For scientists I am looking for outstanding scientific
achievement and in particular out-of-the-box thinking. Folks in any
country are eligible.”
Self-nominations are permissible. Knoepfler plans to pick five
finalists and interview them by phone. He also plans an online vote
that he said “may” influence his decision.
Source:Stem Cell Therapy
Comments Off on ‘The Knoepfler Award:’ Recognizing Risk and Those Who Make a Difference |
November 25th, 2012
California Stem Cell Agency Blogs on Geron Clinical Trial
By Dr. Matthew Watson
The California stem cell agency
published an article online last week concerning the hESC clinical
trial that Geron abandoned last year, dealing mainly with one of the
participants in the program.
about whether the $3 billion research program is likely to fund the
trial once again, should BioTime, Inc., of Alameda, Ca., be
successful in acquiring the assets of once was the first hESC
clinical trial in the United States. The agency loaned Geron $25
million a few months before the company cancelled the trial.
manager, simply wrote,
“They (BioTime) would need to apply
for a loan if they want CIRM to financially support the continued
trial.”
BioTime could apply for has a deadline of Dec. 18 for letters of
intent. In addition to a loan, a grant is also a possibility.
enrolled in the clinical trial shortly before Geron said it was
dropping the effort for financial reasons. Adams interviewed Sharify
before an audience of scientists.
“Katie told me that it would be
impossible not to hope that a trial would help her, but that by the
time she made the decision to participate she knew she was doing it
to further science, not necessarily to further her own recovery. She
told the audience, 'I was part of something that was bigger than me,
and bigger than all of you.'”
UC Davis also wrote about the BioTime-Geron deal last week. Noting
that Geron's decision a year ago left many “upset to put it
mildly,” Knoepfler said the “idea of BioTime buying the Geron
stem cell program is a great one that provides new hope on many
levels.”
Source:Stem Cell Therapy
Comments Off on California Stem Cell Agency Blogs on Geron Clinical Trial |
November 25th, 2012
Researcher Alert: Keeping Tabs on the Stem Cell Exchequer
By Dr. Matthew Watson
The California stem cell agency has
posted the dates for meetings of its board of directors for 2013
with most of the sessions scheduled for the San Francisco Bay Area.
Diego in August, and another in Los Angeles 13 months from now. The
other five are in Northern California. Not yet on the schedule is a board workshop in early January that will be open to the public.
and others? The board controls the purse strings to $3 billion for research grants and determines what areas are to be funded. Astute scientists would do well to take in the sessions.
They offer insights into board thinking and opportunities to deal
with the agency staff and directors on an informal basis. Only a
handful of researchers – or less – attend the meetings on a
regular basis, but have been well-served by the time spent.
Source:Stem Cell Therapy
Comments Off on Researcher Alert: Keeping Tabs on the Stem Cell Exchequer |
November 25th, 2012
Scientists pushing Genetic engineering ahead despite strong opposition to GM … – Economic Times
By Dr. Matthew Watson
 Economic Times | Scientists pushing Genetic engineering ahead despite strong opposition to GM ... Economic Times Siva Reddy of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in Delhi is developing a better way of using agricultural waste. He is engineering plant choloroplasts - the machinery that fixes sunlight - to make cellulase, an ... |
Uncategorized
Comments Off on Scientists pushing Genetic engineering ahead despite strong opposition to GM … – Economic Times |
November 18th, 2012
Biotechnology Spurs Talk At Food Dialogues – Farm Futures
By Dr. Matthew Watson
 Farm Futures | Biotechnology Spurs Talk At Food Dialogues Farm Futures The third panel held at The Food Dialogues in New York City covered "Your Toughest Questions Answered on Biotechnology and Your Food." Moderated by Ali Velshi, CNN chief business correspondent, panelists included Dr. Bob Goldberg, plant molecular ... Final Panel Thoughts from USFRA Food DialoguesAgWired U.S. Farmers & Ranchers Alliance Names Nine Finalists For Its Faces Of ...Beef Magazine |
Uncategorized
Comments Off on Biotechnology Spurs Talk At Food Dialogues – Farm Futures |
November 18th, 2012
Cultivator of Brain Parts
By Dr. Matthew Watson
Yoshiki Sasai is not just an ordinary tissue engineer who tries to coax stem cells to grow into fully formed bodily structures. It is true that Sasai has made his mark by taking on big projects like using stem cells to whip up a retina, cortical tissue and the cerebellum, involved with balance and movement. But his research has gone deeper by delving into the way stem cells organize themselves into complex structures under the influence of genes and the prenatal environment. Read a profile of Sasai here to accompany “ Grow Your Own Eye ,” Sasai’s own account of growing a retina in the November Scientific American .
http://rss.sciam.com/click.phdo?i=7291cadd43ac0cf30e9687431d559702
Uncategorized
Comments Off on Cultivator of Brain Parts |
November 18th, 2012
How to Grow a Retina from Stem Cells (preview)
By Dr. Matthew Watson
In the womb, a ball of identical cells gives rise to varied cell types that ultimately form highly ordered structures and then the full panoply of organs in the human body. The process advances according to an internal biological script that directs each fold and crease of tissue to assume exactly the proper shape and dimension.
http://rss.sciam.com/click.phdo?i=1e6abdd024c3b29c15070219c99ad16a
Uncategorized
Comments Off on How to Grow a Retina from Stem Cells (preview) |
November 18th, 2012
Geron, BioTime Deal Moves Forward with Letter of Intent
By Dr. Matthew Watson
Geron Corp., which once pioneered human
embryonic stem cell research, is close to selling off its hESC business in a complicated deal involving two former CEOs of the company and
BioTime, Inc., of Alameda, Ca.
announced a “letter of intent” involving a transaction in which
BioTime would acquire the assets of Geron's hESC clinical trial that
the company suddenly abandoned last year. The firm also laid off 66 people,
about 40 percent of its staff.
few months after the $3 billion California stem cell agency loaned Geron $25 million to assist in the trial. The agency could
restore the loan for the trial, but the Geron-BioTime announcement
did not mention that possibility. The California Stem Cell Report has
asked the agency for comment.
one day after Geron announced that it was giving up the hESC spinal injury trial because of financial reasons. The Menlo Park, Ca., firm
has been trying to sell its hESC assets since then. BioTime has
been the only firm to express public interest. The Geron trial was
the first hESC trial approved by the FDA.
West, who founded Geron and is now head of Biotime, and Tom Okarma,
who was CEO of Geron from 1999 to 2011. Okarma is now head of BioTime
Acquisition Corp.,(BAC) a subsidiary of BioTime.
described the deal in which BioTime would acquire Geron's
“intellectual property and other assets related to Geron’s
discontinued human embryonic stem cell programs.”
“ BioTime would contribute
to BAC $5 million in cash, $30 million of BioTime common
shares, warrants to purchase eight (8) million common shares
of BioTime at a pre-specified price, rights to use certain
human embryonic stem cell lines, and minority stakes in two of
BioTime’s subsidiaries. In addition, a private investor would
invest $5 million in cash in BAC.
“Following consummation of the
potential transaction, Geron stockholders would receive
shares representing 21.4% of the common stock of BAC as well as
warrants to purchase 8 million shares of BioTime common
stock at a pre-specified price. BioTime would own
approximately 71.6%, and a private investor would own approximately
7.0% of the outstanding BAC common stock for their $5
million investment. BioTime would also receive
warrants that would enable it to increase its ownership in BAC by
approximately 2%, which would reduce the Geron stockholders’
ownership in BAC to 19.2%. BAC would also be committed to pay
to Geron royalties on the sale of products that are
commercialized in reliance upon Geron patents acquired by
BAC.”
intent, an article earlier this week by Vickie Brower in The Scientist said,
“The offer couldn’t come at a
better time for Geron, which in recent months has started to feel
pressure from its shareholders to boost its stock price and move
products through the pipeline. Since last November, when the company
announced its decision to shutter its hESC and regenerative medicine
business and funnel its resources into developing telomerase-related
treatments for cancer, the stock price has dropped more than 50
percent to $1.30 a share. Geron claimed the move was simply to save
money, but many took the decision—which effectively terminated a
clinical trial of an hESC treatment for spinal cord injury—as a
setback for the entire field."
News coverage of yesterday's
announcement was light. Here is a link to a piece by Ryan McBride on
Fierce Biotech.
yesterday and rose to $1.24 in after hours trading. BioTime closed at
$2.97. No after hours trading was reported for BioTime.
Source:Stem Cell Therapy
Comments Off on Geron, BioTime Deal Moves Forward with Letter of Intent |
November 18th, 2012
BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial
By Dr. Matthew Watson
The California stem cell agency said
today it does not plan to reactivate the $25 million loan to assist
in Geron's spinal injury clinical trial despite an impending deal that would turn the effort over to BioTime, Inc.
public communications for the agency, said BioTime will have to
compete in an upcoming award round if it wants to win California
dollars.
California Stem Cell Report, McCormack said,
“That (earlier) loan was specific to
Geron and when the trial was ended the loan ended too. Of course if
Biotime and Geron do complete their deal then Biotime would be free
to apply to us for a new disease team grant.”
could also compete in other appropriate rounds, including the
strategic partnership round just posted by CIRM. It provides for four
awards of up to $15 million. Funding could come as early as October
of next year. The strategic partnership round is a business-friendly
effort that is aimed at attracting “industry engagement and
investment.” The deadline for letters of intent is Dec. 18.
million loan to Geron in 2011 just a few months before the Menlo Park
firm abandoned its human embryonic stem cell trial for financial
reasons. (The full text of the loan agreement can be found here.) The company has repaid the loan with interest.
assets associated with the clinical trial since last November. The only public
interest that has surfaced has come from BioTime, Inc., of Alameda,
Ca. Michael West, founder of Geron, is the CEO of BioTime. Tom
Okarma, CEO of Geron from 1999 to 2011, is CEO of the BioTime
subsidiary that would assume the clinical trial.
be published soon, according to a story in the San Francisco Business
Times by Ron Leuty. He quoted CIRM President Alan Trounson as saying
that “some findings” from the trial would be published next month
in a medical journal.
time of this writing today, up from $1.21 yesterday. BioTime's stock
stood at $2.99, up from $2.97.
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/DS-6n2DoRy0/biotime-will-have-to-compete-for.html
Stem Cell Therapy
Comments Off on BioTime Will Have to Compete for California Cash for Geron’s Dormant Clinical Trial |
November 18th, 2012
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at …
By Dr. Matthew Watson
JERUSALEM--(BUSINESS WIRE)--
Gamida Cell Ltd., a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine, announced today that the first patient, enrolled in its pilot study of NiCord as an investigational treatment for sickle cell disease (SCD), has been transplanted at Duke University in North Carolina.
Gamida Cell CEO Dr. Yael Margolin said, The NiCord study is a first step in broadening Gamida Cells pipeline of cell therapies to treat patients who suffer from severe non-malignant diseases with a very large unmet clinical need.
SCD is a group of inherited red blood cell disorders where red blood cells become hard and sticky and look like a C-shaped farm tool called a sickle. According to statistics, SCD affects 90,000 to 100,000 in the US alone, mainly African-Americans and Hispanic-Americans. Symptoms range in type and severity. SCD can be fatal and to date, the only cure for SCD is stem cell transplantation from a family related matched donor.
Dr. Margolin continued, Sickle cell disease can be cured with a successful bone marrow transplantation, especially from a family related fully matched donor. Most patients do not pursue this option, since they do not have the suitable donor. NiCord is intended to reverse this situation and provide a readily available cure.
NiCord is an expanded cell graft derived from an entire unit of umbilical cord blood and enriched with stem cells. NiCord was developed based on Gamida Cells proprietary NAM technology.
The official name of the study is Allogeneic Stem Cell Transplantation of NiCord, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Sickle Cell Disease. http://www.clinicaltrials.gov/ct2/show/NCT01590628?term=nicord&rank=1. A total of 10 patients, ages 2 21, will be enrolled in the NiCord study, a single center, single arm trial evaluating the safety and efficacy of transplanting NiCord together with a second un-manipulated cord blood unit in patients with SCD following myeloablative therapy. The study will also assess transplant-related mortality, event-free survival and overall survival at 100, 180 and 365 days, respectively.
About Gamida Cell
Gamida Cell is a world leader in stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. The companys pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine. Gamida Cells therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood, bone marrow and peripheral blood, which are expanded in culture. Gamida Cells current shareholders include: Elbit Imaging (EMITF), Clal Biotechnology Industries (CBI.TA), Israel Healthcare Venture, Teva Pharmaceutical Industries (TEVA), Amgen, Denali Ventures and Auriga Ventures. For more information, please visit: http://www.gamida-cell.com.
Read the original:
First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at ...
Uncategorized
Comments Off on First Pediatric Sickle Cell Disease Patient Receives NiCord® Stem Cell Transplantation in Gamida Cell Pilot Study at … |
November 13th, 2012
Cell Therapy Industry Group Welcomes its 4,000th member
By Dr. Matthew Watson
I'm pleased to point out that today the LinkedIn Cell Therapy Industry Group welcomed its 4,000th member today.
The Cell Therapy Industry group was created to serve as a network of those in the cell therapy industry. The group acts as a vehicle for referrals, networking, information, and facilitating collaboration. The group's focus is on the activities of companies in and serving the space.
The group began in July 2008. It took 2.5 years to reach the first 1000 members, 9 mos to reach 2,0000, 6 months to reach 3,000, and 6 months to meet today's 4,000 member mark.
As is typical, there is a very high percentage of passive participants but the group benefits from an avid group of participants who post, share, exchange, and debate on a range of topics ranging from regulatory, clinical, commercial, scientific, manufacturing, financial, and other topics of interest to the group.
As the group has grown I've noted two trends pertaining to the composition of the membership: (a) having tapped out the c-level suite, growth is increasingly coming from down the hierarchy of the corporate food chain and including those in the operational trenches, and (b) a much higher ratio of new members of late is from outside the US, presumably as LinkedIn increasingly penetrates OUS markets.
We strive hard to maintain the quality of the participation by screening each applicant, deleting off-topic posts, moving promotional posts to the "promotions" tab" and encouraging a balance of news-sharing with useful discussion threads.
I'm proud to say the group has become a vibrant and valuable part of the sector due to the hard work and contributions of all involved.
As these kind of virtual networks become exponentially larger and provide different value than the professional societies representing the sector, I will be fascinated to watch if and how this affects how sectors like our interact and how this will impact the traditional value proposition of member-based professional societies.
If you are not a member of the LinkedIn Cell Therapy Industry Group, check it out.
--Lee
Regenerative Medicine
Comments Off on Cell Therapy Industry Group Welcomes its 4,000th member |
November 11th, 2012
Two Years On, Stem Cells Still Healing Damaged Hearts
By Dr. Matthew Watson
By E.J. Mundell HealthDay Reporter
TUESDAY, Nov. 6 (HealthDay News) -- Updated two-year results from a small trial using cardiac stem cells to repair damaged hearts suggest the treatment's healing effect persists.
Patients with heart failure caused by prior heart attacks who got the treatment continue to see reductions in cardiac scar tissue, improvements in the heart's pumping ability and even a boost in their quality of life, researchers said.
These improvements seem to be continuing as time goes on, suggesting that stem cell therapy's healing power hasn't diminished.
"Now we need to perform larger and randomized, blinded studies ... to confirm this data," said study lead author Dr. Roberto Bolli, director of the Institute of Molecular Cardiology at the University of Louisville.
His team presented its results Tuesday at the American Heart Association's annual meeting, in Los Angeles.
According to the AHA, more than 6 million Americans suffer from heart failure, a gradual weakening of the heart often caused by damage from a prior heart attack. Despite its prevalence and lethality, virtually no advance has been made over the past few decades in doctors' ability to treat or reverse heart failure.
That's why the advent of stem cell therapy has encouraged researchers. Stem cells have the ability to turn into myriad living cells, and the hope is that once infused into the heart they can help repair it.
This trial is the first human trial to test this theory using the patient's own cardiac stem cells. The cells used in the trial were harvested from 33 heart failure patients who were undergoing bypass surgery. The cells were then coaxed to multiply into the millions in the lab and then transplanted back into 20 of the patients. The remaining 13 patients did not receive a stem cell infusion and are the "control" group for comparison purposes.
Results gathered one year after treatment showed improvements for the treated patients, but experts questioned whether those gains would fade over time.
See the original post:
Two Years On, Stem Cells Still Healing Damaged Hearts
Cardiac Stem Cells
Comments Off on Two Years On, Stem Cells Still Healing Damaged Hearts |
November 10th, 2012
Govt. Appoints Task Force To Explore Stem Cell Research – Video
By Dr. Matthew Watson
Govt. Appoints Task Force To Explore Stem Cell Research
Minister of Health Hon. Dr. Perry Gomez announced that the government has appointed a 10 member task force, charged with making recommendations to the government to explore stem cell therapy in The Bahamas.From:ZNSNetworkViews:5 0ratingsTime:03:27More inNews Politics
Read the original post:
Govt. Appoints Task Force To Explore Stem Cell Research - Video
Uncategorized
Comments Off on Govt. Appoints Task Force To Explore Stem Cell Research – Video |
November 8th, 2012
Stem cell therapy to be regulated in PH
By Dr. Matthew Watson
MANILA, Philippines -- The Department of Health (DOH) has announced its plan to regulate stem cell therapy in the country.
Stem cell treatment involves the use of adult stem cells to treat a range of diseases.
The Health Department believes that because of the complex preparation and invasive procedure involved, there needs to be a regulatory framework to protect Filipino citizens.
The regulation of laboratories and practitioners involves five key points.
First is a check on the credentials of people involved in the service, as stem cell treatment is a specialized field. The supply of raw materials will also have to be monitored, making sure especially that they do not come from aborted fetuses.
Laboratories will be scrutinized for their procedures, sanitation and safety. Therapeutic claims, on the other hand, are also up for strict assessment, to make sure that these are based on solid scientific evidence.
Finally, the DOH also wants a report on the possible failure of treatments, to find out if there are negative outcomes to stem cell therapy.
"Those who are going to other countries for stem cell treatment should also check if their destination allows stem cell tourism," clarified FDA Acting Director Dr. Kenneth Hartigan-Go.
The DOH said consultations with stakeholders are still ongoing, but it expects a set of guidelines to be released by next month.
See original here:
Stem cell therapy to be regulated in PH
Uncategorized
Comments Off on Stem cell therapy to be regulated in PH |
November 8th, 2012
The Patients of Angeles Health International – Video
By Dr. Matthew Watson
The Patients of Angeles Health International
What our patients have to say about their experiences at Angeles Health International. All patients were treated for different conditions, in separate departments throughout our facilities. Angeles Health International offer cutting edge care, procedures and treatment in the following areas: Weight Loss Surgery - http://www.weightlossmex.com Stem Cell Therapy - http://www.stemcellmx.com Multiple Sclerosis Treatment - http://www.ccsvi.mx Effective Chemotherapy-free Cancer Treatment - http://www.cancertreatmentmx.com Visit the Angeles Health International website here: http://www.angeleshealth.com There are a team of healthcare professionals waiting to hear from you. Contact Angeles Health International toll free on: 1.866.668.9263From:AngelesHealthViews:5 0ratingsTime:03:06More inScience Technology
Visit link:
The Patients of Angeles Health International - Video
Uncategorized
Comments Off on The Patients of Angeles Health International – Video |
November 6th, 2012
Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina
By Dr. Matthew Watson
RIO DE JANEIRO--(BUSINESS WIRE)--
CryopraxisTM/CellPraxis aims to start patient recruitment for its Phase III Refractory Angina Cell Therapy Brazilian arm clinical trial by the end of 2012 or early 2013. The phase IIA/B clinical trial study was completed in December 2011. These trials involved the use of a proprietary autologous stem cell formulation (MonocellTM) indicated for neoangiogeneses.
Safety and efficacy of this product was evaluated in patients with refractory angina, a no option disease condition, characterized by severe chest pain for which there is no efficient treatment available, says the President of both Companies, Eduardo Cruz.
ReACT, MonocellTMs derived product, showed evidence of safety and efficacy in our initial clinical trials. All patients included in this trial were classified as Class IV Angina in CCSAC* (the most severe class of chest pain). In the first group of patients, whose data was published**, there was a progressive and sustained improvement in angina symptoms, with 87.5% of the patients completing the clinical trial with a CCSAC score of 0 or 1.
Angina symptom relief began as early as 3 months post procedure with continuing improvement through the 18th month, suggesting that angiogenesis began early, and that it kept evolving 18 months after the procedure. Objective evaluation of stress myocardium perfusion (scintigraphic analysis), after 1 year of follow-up, gave indications of complete myocardial reperfusion in 75% of the patients, says Dr. Nelson Hossne, Medical Director of CellPraxis. Our conclusion was ReACT's specific cell formulation, MonoCell, had a direct correlation to myocardial neoangiogeneses.
About CryopraxisTM (www.cryopraxis.com.br) and CellPraxis (www.cellpraxis.com)
Located at Bio-Rio Biotech Cluster (Rio de Janeiro, Brazil), CryopraxisTM is the pioneer and the largest bank of umbilical cord blood in Brazil and has been in operation since 2001, with approximately 25,000 customers. CellPraxis is a bioengineering company that invests in research projects involving stem cell therapy. Some of these projects are conducted in partnership with institutions like the Federal University of Rio de Janeiro, Federal University of So Paulo, the University of South Florida and Saneron CCEL Therapeutics, Inc. (a USA based biotechnology company dedicated to stem cell research).
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.
Read the original here:
Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina
Uncategorized
Comments Off on Cardiac Cell Therapy Phase III Trial to Treat Refractory Angina |
November 6th, 2012
FAQ-14 of 19: Do We Offer a Guarantee for Our Stem Cell Therapy? – Video
By Dr. Matthew Watson
FAQ-14 of 19: Do We Offer a Guarantee for Our Stem Cell Therapy?
youtu.be Yes, a reasonable guarantee is provided, and you can learn more of it in this video. When you want more than this, visit bit.ly for personalized details of how stem cell therapy can benefit you.From:Harvey WallbangerViews:0 0ratingsTime:01:15More inPeople Blogs
Originally posted here:
FAQ-14 of 19: Do We Offer a Guarantee for Our Stem Cell Therapy? - Video
Uncategorized
Comments Off on FAQ-14 of 19: Do We Offer a Guarantee for Our Stem Cell Therapy? – Video |
November 5th, 2012
FAQ-12-19: Are Our Stem Cell Physicians Qualified in Stem Cell Therapy? – Video
By Dr. Matthew Watson
FAQ-12-19: Are Our Stem Cell Physicians Qualified in Stem Cell Therapy?
youtu.be Are our stem cell doctors qualified in stem cell therapy? The straight answer to this question might surprise you, but only if you think stem cell therapy is a therapy that was approved for certain patients just THIS year. And for more surprising, encouraging details on stem cell therapies and your particular case, visit bit.ly today.From:VeteransRecallViews:0 0ratingsTime:00:55More inScience Technology
The rest is here:
FAQ-12-19: Are Our Stem Cell Physicians Qualified in Stem Cell Therapy? - Video
Uncategorized
Comments Off on FAQ-12-19: Are Our Stem Cell Physicians Qualified in Stem Cell Therapy? – Video |
November 5th, 2012
FAQ-14 of 19: Your Stem Cell Therapy Has a Guarantee for Stem Cell Treatments? – Video
By Dr. Matthew Watson
FAQ-14 of 19: Your Stem Cell Therapy Has a Guarantee for Stem Cell Treatments?
youtu.be This video addresses the ethical, practical aspects of a #39;guarantee #39; for stem cell therapy or stem cell treatments. For more detailed information concerning guarantees, stem cell therapy and your particular problem, visit bit.ly today.From:Lek WorkerViews:0 0ratingsTime:01:15More inNonprofits Activism
Here is the original post:
FAQ-14 of 19: Your Stem Cell Therapy Has a Guarantee for Stem Cell Treatments? - Video
Uncategorized
Comments Off on FAQ-14 of 19: Your Stem Cell Therapy Has a Guarantee for Stem Cell Treatments? – Video |
November 5th, 2012